Search - tctmd.com

Displaying 1 - 20 of 57

Sort: Relevancy | Date

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

News Conference News ACC 2024

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

Yael L. Maxwell

April 05, 2024

Presentation ACC 2023

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

Presenter: John K. Forrest

March 05, 2023

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

Todd Neale

March 05, 2023

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

L.A. McKeown

April 07, 2020

News Conference News ACC 2020

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

Michael O'Riordan

April 06, 2020

News Conference News ACC 2020

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Michael O'Riordan

March 29, 2020

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

News Conference News ACC 2019

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Yael L. Maxwell

March 17, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

Presentation ACC 2019

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Presenter: Martin B. Leon

March 17, 2019

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

Caitlin E. Cox

March 19, 2018

Advertisement

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Dapagliflozin after Transcatheter Aortic Valve Implantation

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content